✨ Your Portfolio is fetched and updated from zerodha.
Small Chemicals

Tatva Chintan Pharma Chem Ltd.

TATVA

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹3,293 Cr.
P/E
460.26

Tatva Chintan Pharma Chem Ltd.

  • Tatva Chintan Pharma
  • Vishnu Chemicals
  • Camlin Fine Sciences
  • TJI Speciality Chemicals
FAQs on Tatva Chintan Pharma Chem Ltd. Shareprice

Tatva Chintan Pharma has given lower returns compared to its competitors.
Tatva Chintan Pharma has grown at ~-9.9% over the last 4yrs while peers have grown at a median rate of 2.32%

Yes, Tatva Chintan Pharma is expensive.
Latest PE of Tatva Chintan Pharma is 460, while 3 year average PE is 117.
Also latest EV/EBITDA of Tatva Chintan Pharma is 85.16 while 3yr average is 53.1.

View FAQ's On Business
Growth Table
  • Tatva Chintan Pharma Chem Ltd.
  • Vishnu Chemicals
  • Camlin Fine Sciences
Balance Sheet
  • Tatva Chintan Pharma Chem Ltd.
  • Vishnu Chemicals
  • Camlin Fine Sciences
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Tatva Chintan Pharma Chem Ltd.
  • Vishnu Chemicals
  • Camlin Fine Sciences
Cash Flow
  • Tatva Chintan Pharma Chem Ltd.
  • Vishnu Chemicals
  • Camlin Fine Sciences
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Tatva Chintan Pharma Chem Ltd.
  • Vishnu Chemicals
  • Camlin Fine Sciences
Quarterly Results
  • Tatva Chintan Pharma Chem Ltd.
  • Vishnu Chemicals
  • Camlin Fine Sciences
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Tatva Chintan Pharma Chem Ltd. Financials

Balance sheet of Tatva Chintan Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Tatva Chintan Pharma is increasing.
Latest net debt of Tatva Chintan Pharma is ₹8.28 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹62.23 Crs.

The profit is oscillating.
The profit of Tatva Chintan Pharma is ₹7.16 Crs for TTM, ₹5.71 Crs for Mar 2025 and ₹30.35 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Tatva Chintan Pharma latest dividend payout ratio is 40.95% and 3yr average dividend payout ratio is 22.03%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Accounts Receivable, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech